Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3PD2C)

Drug Name
Fluoxetine Drug Info
Synonyms
Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetinum; Fluval; Fontex; Portal; Pulvules; Reconcile; Reneuron; Fluoxetina [Spanish]; Fluoxetine Hcl; Prozac Weekly; Animex-On; Fluoxetina [INN-Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetinum [INN-Latin]; Lilly-110140; Prozac (TN); Fluoxetine (USAN/INN); Fluoxetine [USAN:INN:BAN]; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
Therapeutic ClassAntidepressants
Cross-matching ID
PubChem CID
3386
ChEBI ID
CHEMBL41
CAS Number
CAS 54910-89-3
TTD Drug ID
D0TR5X
VARIDT Drug ID
DR00459
INTEDE Drug ID
DR0720
ACDINA Drug ID
D00283

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.40 0.00e+0 19/20 (95%) MSMO1;NSDHL;SQLE;...
Terpenoid backbone biosynthesis 2.20 0.00e+0 18/22 (81.82%) HMGCS1;ACAT2;IDI1;...
PPAR signaling pathway 2.01 0.00e+0 66/74 (89.19%) SCD;HMGCS1;FABP4;...
Biosynthesis of unsaturated fatty acids 1.88 1.50e-2 21/27 (77.78%) SCD;FADS1;ELOVL6;...
Butanoate metabolism 1.76 4.40e-2 23/28 (82.14%) HMGCS1;ACAT2;AACS
Fatty acid biosynthesis 1.74 4.44e-2 16/18 (88.89%) FASN;ACSL1;ACSL3;...
TNF signaling pathway -1.69 4.69e-2 103/112 (91.96%) IL1B;CXCL10;FAS;...
Rheumatoid arthritis -1.69 4.83e-2 78/93 (83.87%) IL1B;ANGPT1;TGFB2;...
Glycolysis / Gluconeogenesis -1.71 4.25e-2 56/67 (83.58%) LDHB;PGK1;ALDH3B1;...
IL-17 signaling pathway -1.74 2.99e-2 84/94 (89.36%) MAPK8;IL1B;CXCL10;...
Protein export -1.75 3.14e-2 17/23 (73.91%) SEC62;SRP9;SEC11A;...
Arginine and proline metabolism -1.75 3.18e-2 39/50 (78%) P4HA2;ALDH18A1;ALDH2;...
AGE-RAGE signaling pathway in diabetic complications -1.77 2.30e-2 97/100 (97%) PLCG1;TGFBR1;ICAM1;...
Fructose and mannose metabolism -1.77 2.42e-2 30/33 (90.91%) GMPPA;MPI;KHK;...
Bladder cancer -1.79 2.37e-2 40/41 (97.56%) CDH1;KRAS;RASSF1;...
Protein processing in endoplasmic reticulum -1.79 2.53e-2 127/171 (74.27%) CRYAA;EIF2AK3;CKAP4;...
Proximal tubule bicarbonate reclamation -1.81 1.93e-2 21/23 (91.3%) ATP1B2;AQP1;SLC25A10;...
Cocaine addiction -1.83 1.73e-2 42/49 (85.71%) CREB3L1;CDK5R1;CREB1;...
Galactose metabolism -1.85 1.84e-2 26/31 (83.87%) PGM1;B4GALT2;B4GALT1;...
Starch and sucrose metabolism -1.88 1.38e-2 25/36 (69.44%) PGM1;GYS1;ENPP1;...
Ribosome -1.93 1.38e-2 113/158 (71.52%) RPL10L;RPL36A;RPL27A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H